[헬스케어 소식] Seegene signs technology sharing agreement with Spain’s No. 1 diagnostic company ‘Wefen’

New corporation launched in Spain in the first half of next year
Developing infectious disease products using PCR technology

Seegene, a global molecular diagnostics total solution company, is launching its ‘Technology Sharing Project’, a global business strategy promoted to prevent future pandemics and realize a world free from diseases.

Seegene announced on the 8th that it has signed a final contract for technology sharing business with Wefen, Spain’s No. 1 diagnostics company, and confirmed to establish a corporation in Spain. As the two companies complete the final contract, the new corporation Weppen-Seegene is expected to be launched in the first half of next year as soon as the government approval process for each country is completed.

This is the result achieved two years after Seegene and Weppen began discussions on technology sharing business collaboration, and is the second achievement following Israel’s Hilabs-Seegene corporation, which concluded a corporation establishment agreement in March of last year. As a result, Seegene has concluded contracts with its first and second overseas partners who have confirmed their participation in the technology sharing project.

The technology sharing project shares diagnostic and data analysis technologies that combine Seegene’s unique technological capabilities and know-how, including syndromic quantitative PCR technology and the automated reagent development system (SGDDS), with leading companies in each country.

Experts, including scientists from all over the world, participate to develop local customized diagnostic products in various fields related to various diseases of humans, animals and plants, thereby creating ‘a world free from all diseases’, ‘a world free from cancer and various infectious diseases’, ‘not only for humans but for all animals and plants.’ The ultimate goal is to create a world without disease.

Seegene’s syndromic quantitative PCR technology can test up to 14 pathogens that cause similar symptoms in one tube, and when conducting a panel test using multiple tubes, dozens of major pathogens can all be identified, allowing for multiple infections and quantitative detection. It is evaluated as an unrivaled technology for providing information.

In particular, as the possibility of complex pandemics caused by multiple viruses occurring simultaneously in multiple regions is increasing due to recent climate change, it is considered the optimal technology to quickly respond to mutations that change rapidly in various forms.

Companies participating in the technology sharing project will have the infrastructure to develop and produce locally optimized syndromic quantitative PCR products in their own country based on the world-class PCR technology and know-how provided by Seegene, which will enable Outbreak (Outbreak) in the future. Even if a small-scale local infection or complex pandemic occurs, we will have the ability to respond quickly on our own without relying on external sources.

Regarding the operation of the Weppen-Seegene corporation, Seegene plans to share core technologies with the corporation, while Weppen plans to further strengthen its market competitiveness by developing products optimized for Spain based on its abundant infrastructure and network in the local market. As the region is one where new infectious diseases and virus mutations occur frequently, Weppen-Seegene Corporation plans to prioritize the development of infectious disease products such as drug resistance testing, blood testing, organ transplant patient monitoring testing, and sexually transmitted infection (STI) testing. .

The Weppen-Seegene corporation is expected to serve as a trigger to expand Seegene’s technology sharing business not only in Europe but also around the world.

Spain is not only the fourth largest in vitro diagnostic (IVD) market in Europe, but is also considered a strategic location for expanding technology sharing business regionally. Accordingly, Weppen-Seegene Corporation is expected to play a leading role in obtaining approval under the European In Vitro Diagnostic Medical Device Regulations (CE-IVDR) and entering the global market, including Europe.

Carlos Pascual, CEO of Weppen, said, “Weppen has exerted significant influence in the healthcare field through syndromic PCR diagnostic tests in cooperation with Seegene over the past 10 years, and provides Seegene’s unrivaled development and production technology and know-how. “We are pleased to have received the approval and established the Weppen-Seegene corporation,” he said. He continued, “Spain and Portugal are markets with high demand for product development due to new infectious diseases and virus mutations,” and added, “Through this partnership, we will be able to quickly respond to the spread of any infectious disease in the future.”

Seegene CEO Cheon Jong-yoon said, “I have high expectations for the Weppen-Seegene corporation, which will have Weppen’s long-term business experience and Seegene’s world-class syndromic product development and production capabilities,” adding, “The world will continue to be interested in technology sharing business.” “We will share Seegene’s technology with leading companies in each country,” he said.

The technology sharing project is being carried out with the active participation of Microsoft and Springer Nature. Microsoft, participating as a technology partner, is also providing business support in addition to cooperation in the field of development automation, such as combining Seegene’s SGDDS with Azure Open AI services.

fitness >

I also recommend these subscriptions!

• 

  Seo Young-ah’s 100-year-old cafe

• 

  editorial

• 

  today’s horoscope

Reporter Ahn So-hee [email protected]

• great

  0dog

• I’m sad

  0dog

• I’m angry

  0dog

• I recommend it

  dog

Hot news now